Alnylam Pharmaceuticals ALNY Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| AMVUTTRA | $889.93M+7.7% | $826.59M+20.6% | $685.3M+39.3% | $491.95M+58.7% | $309.99M+8.2% | |
| GIVLAARI | $74.39M-14.3% | $86.8M+17.5% | $73.87M-8.6% | $80.85M+20.7% | $66.97M+3.6% | |
| ONPATTRO | $20.48M-35.4% | $31.69M-18.9% | $39.08M-25.6% | $52.54M+6.2% | $49.49M-11.8% | |
| OXLUMO | $51.32M+3.4% | $49.65M-6.0% | $52.83M+12.7% | $46.87M+11.4% | $42.09M-3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alnylam Pharmaceuticals break its business down?
- Alnylam Pharmaceuticals (ALNY) reports total revenues by product across 4 parts — AMVUTTRA, GIVLAARI, ONPATTRO and OXLUMO. Each is extracted from the segment footnotes and tracked over time.
- Where does Alnylam Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alnylam Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
